Assessment of New Molecular Entities Approved for Cancer Treatment in 2020-Reference-Cited by-同舟云学术

Assessment of New Molecular Entities Approved for Cancer Treatment in 2020

Published:2021-05-28 Issue:5 Volume:4 Page:e2112558
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Smith Claire E. P.¹,Prasad Vinay²³

Affiliation:

1. Hematology and Medical Oncology, Boston University School of Medicine, Boston, Massachusetts

2. Department of Medicine, University of California, San Francisco

3. Department of Epidemiology and Biostatistics, University of California, San Francisco

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2780442/smith_2021_ld_210097_1621539689.57747.pdf

Reference6 articles.

1. Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology survey.;Waterhouse;JCO Oncol Pract,2020

2. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology.;Haslam;Eur J Cancer,2019

3. Reputation and precedent in the bevacizumab decision.;Carpenter;N Engl J Med,2011

4. US Food and Drug Administration. FDA Approves First Treatment for COVID-19. Food and Drug Administration news release. Published October 22, 2020. Accessed December 4, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19

5. Hahn? SM (@SteveFDA). As we make progress in our understanding of #COVID19, we continue full speed ahead on our non-COVID cancer-related work, including important drug approvals. For instance, as of Oct. 30, the @US_FDA has approved 42 novel drugs including 15 new drugs to treat patients with various forms of cancer. Several of these approvals have been “firsts” for oncology. November 17, 2020. Accessed April 15, 2021. https://twitter.com/stevefda/status/1328800222449979392

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Efficacy and Mechanism of Action of Recently FDA Approved Anticancer Drugs: An Updated Review;Current Cancer Therapy Reviews;2024-04-09

2. Is Target-Based Drug Discovery Efficient? Discovery and “Off-Target” Mechanisms of All Drugs;Journal of Medicinal Chemistry;2023-09-06

3. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021;JAMA Network Open;2022-03-15

4. Quality of biomarker defined subgroups in FDA approvals of PD ‐1/ PD‐L1 inhibitors 2014 to 2020;International Journal of Cancer;2022-02-26